The abstract is read at the publisher; the summary is JClub's.
In first-line metastatic uveal melanoma, darovasertib plus crizotinib produced an overall response rate of 34.1% and median overall survival of 21.1 months in 44 treatment-naïve patients.
- Why it matters: Metastatic uveal melanoma has poor prognosis and limited options, and most tumors carry GNAQ/11 mutations that activate PKC, creating a need for targeted therapies.
- What they did: In the phase 2 expansion of OptimUM-01, previously untreated patients with measurable disease received darovasertib 300 mg twice daily plus crizotinib 200 mg twice daily, with safety and efficacy assessed by ORR, DOR, DCR, PFS, and OS.
- The result: Common adverse events included diarrhea (95.2%) and nausea (84.1%), with grade 3+ events including pulmonary embolism (9.1%) and iron deficiency anemia (6.8%); efficacy included DOR of 9.0 months, DCR of 90.2% at 8 weeks, and median PFS of 7.0 months.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.